BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Ozaki K, Harada K, Terayama N, Kosaka N, Kimura H, Gabata T. FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background. Jpn J Radiol 2020;38:697-718. [PMID: 32246350 DOI: 10.1007/s11604-020-00961-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Paspulati RM, Gupta A. PET/MR Imaging in Cancers of the Gastrointestinal Tract. PET Clin 2016;11:403-23. [PMID: 27593246 DOI: 10.1016/j.cpet.2016.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
3 Hwang SH, Hong HS, Kim D, Kim GM, Lee HW, Lee M, Kim DY, Park MA, Yun M. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. Clin Nucl Med 2022. [PMID: 35384891 DOI: 10.1097/RLU.0000000000004128] [Reference Citation Analysis]
4 Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Oncology 2021;99:169-76. [PMID: 33207358 DOI: 10.1159/000510754] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Hong CM, Ahn BC, Jang YJ, Jeong SY, Lee SW, Lee J. Prognostic Value of Metabolic Parameters of 18F-FDG PET/CT and Apparent Diffusion Coefficient of MRI in Hepatocellular Carcinoma. Clin Nucl Med 2017;42:95-9. [PMID: 27941378 DOI: 10.1097/RLU.0000000000001478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Hyun SH, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, Hong IK, Oh JK, Chung YA, Song BI, Kim TS, Kim KS, Moon DH, Yun M. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. 2016;43:1638-1645. [PMID: 26936852 DOI: 10.1007/s00259-016-3348-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
7 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
8 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
9 Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB. Value of 18F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. J Dig Dis. 2013;14:433-438. [PMID: 23615075 DOI: 10.1111/1751-2980.12064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Castilla-lièvre M, Franco D, Gervais P, Kuhnast B, Agostini H, Marthey L, Désarnaud S, Helal B. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:852-9. [DOI: 10.1007/s00259-015-3241-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
11 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
12 Lee DS, Kim SJ, Jang HS, Yoo IR, Park KR, Na SJ, Lee KY, Hong SH, Kang JH, Kim YK, Kim YS. Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer. Medicine (Baltimore) 2015;94:e1304. [PMID: 26266371 DOI: 10.1097/MD.0000000000001304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Shin S, Pak K, Kim IJ, Kim BS, Kim SJ. Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer. Nucl Med Mol Imaging 2017;51:233-9. [PMID: 28878849 DOI: 10.1007/s13139-016-0456-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bieze M, Klümpen HJ, Verheij J, Beuers U, Phoa SS, van Gulik TM, Bennink RJ. Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology 2014;59:996-1006. [PMID: 24123111 DOI: 10.1002/hep.26781] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
16 Ortega López N. PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. PET Clin 2015;10:507-17. [PMID: 26384597 DOI: 10.1016/j.cpet.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hwang SH, Lee M, Lee N, Park S, Kim CK, Park MA, Yun M. Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT. Clin Nucl Med 2016;41:296-301. [PMID: 26756099 DOI: 10.1097/RLU.0000000000001105] [Reference Citation Analysis]
18 Kasuya K, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Eguchi Y, Hashimoto M, Kumada H. Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. Intern Med 2021;60:345-51. [PMID: 32963154 DOI: 10.2169/internalmedicine.5185-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045-1051. [PMID: 26985057 DOI: 10.2967/jnumed.115.170076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
21 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
22 Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics 2014;4:736-44. [PMID: 24883123 DOI: 10.7150/thno.8725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
23 Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128-137. [PMID: 25459673 DOI: 10.1016/j.crad.2014.09.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
24 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol 2014; 20(18): 5375-5388 [PMID: 24833867 DOI: 10.3748/wjg.v20.i18.5375] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
27 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
28 Park S, Kim TS, Kang SH, Kim HB, Park JW, Kim SK. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. Medicine (Baltimore) 2018;97:e12311. [PMID: 30212970 DOI: 10.1097/MD.0000000000012311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
29 Zandifar A, Saucedo J, Vossough A, Alavi A, Hunt SJ. Role of Fluorodeoxyglucose-PET in Interventional Radiology. PET Clin 2022:S1556-8598(22)00008-6. [PMID: 35662495 DOI: 10.1016/j.cpet.2022.03.003] [Reference Citation Analysis]
30 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib. Liver Cancer 2020;9:84-92. [PMID: 32071912 DOI: 10.1159/000503577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
31 Vadi SK, Mittal BR, Kumar R, Parihar AS, Shukla J, Kalra N. Demonstration of Treatment Response to Trans-arterial Radio-embolization (TARE) on 68Ga-DOTANOC PET/CT in a Patient With Metastatic Neuroendocrine Tumor. Clin Nucl Med 2018;43:e312-3. [PMID: 29939955 DOI: 10.1097/RLU.0000000000002177] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl. 2015;21:572-580. [PMID: 25644857 DOI: 10.1002/lt.24083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
34 Arslan E, Çermik TF. PET/CT Variants and Pitfalls in Liver, Biliary Tract, Gallbladder and Pancreas. Semin Nucl Med 2021;51:502-18. [PMID: 34049687 DOI: 10.1053/j.semnuclmed.2021.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384-391. [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]